BENGALURU, India, March 30, 2026 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that the company has reached a…
— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET…
NEW YORK, Dec. 22, 2025 /PRNewswire/ -- SOS Limited (NYSE: SOS) ("SOS" or the "Company") announced today that it is…
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…
BENGALURU, India, Dec. 11, 2025 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that the company has been awarded…
MUMBAI, India, Dec. 9, 2025 /PRNewswire/ -- Ashika Investment Managers Pvt. Ltd. has received node from SEBI for launch of…
December 03, 2025 10:00 ET | Source: MATTER MINNEAPOLIS, MN , Dec. 03, 2025 (GLOBE NEWSWIRE) -- MATTER, a Minnesota-based…
LONDON, Dec. 2, 2025 /PRNewswire/ -- Yesterday, the Sustainable Markets Initiative hosted a gathering of Heads of States and Government,…
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases,…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…